Breztri Components
Breztri Aerosphere contains three active ingredients: micronized budesonide (an inhaled corticosteroid), micronized glycopyrrolate (a long-acting muscarinic antagonist/LAMA), and micronized formoterol fumarate (a long-acting beta2-agonist/LABA), delivered via a pressurized metered-dose inhaler with inactive ingredients including hydrofluoroalkane (HFA-134a) propellant and porous particles comprised of DSPC and calcium chloride. 1
Active Components
Breztri Aerosphere is a triple-therapy combination inhaler containing:
- Budesonide (inhaled corticosteroid/ICS) - available in two strengths
- Glycopyrrolate (long-acting muscarinic antagonist/LAMA)
- Formoterol fumarate (long-acting beta2-agonist/LABA)
The medication is available in two dosing strengths: 87/5/9 μg and 172/5/9 μg per actuation 1
Inactive Components
The inactive ingredients in Breztri Aerosphere include:
- Hydrofluoroalkane (HFA-134a) - the propellant that delivers the medication
- Porous particles - comprised of:
- DSPC (1,2-Distearoyl-sn-glycero-3-phosphocholine)
- Calcium chloride
Clinical Significance of Formulation
The extrafine formulation of all three active ingredients allows for enhanced deposition in both large and small airways, which is particularly important for comprehensive asthma and COPD management 2. This single-inhaler triple therapy (SITT) approach consolidates three medications into one device, potentially improving adherence by reducing the complexity of multiple-inhaler regimens 2.
The use of porous particles in the formulation facilitates the creation of extrafine particles that can reach the peripheral airways more effectively than conventional formulations 1.